Real-world use of second-generation integrase strand transfer inhibitors (INSTI) as switch therapy in the prospective ANRS-CO3-AquiVIH-NA cohort
{{output}}
Objectives: To characterize real-world treatment switching in France to bictegravir (BIC or B) or dolutegravir (DTG)-based regimens with a focus on treatment persistence, effectiveness (HIV-1 RNA ≤50 copies/ml) and particular at... ...
